These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 24942912)

  • 1. D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation--observations from the ARISTOTLE trial.
    Christersson C; Wallentin L; Andersson U; Alexander JH; Ansell J; De Caterina R; Gersh BJ; Granger CB; Hanna M; Horowitz JD; Huber K; Husted S; Hylek EM; Lopes RD; Siegbahn A
    J Thromb Haemost; 2014 Sep; 12(9):1401-12. PubMed ID: 24942912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.
    Alexander JH; Wojdyla D; Vora AN; Thomas L; Granger CB; Goodman SG; Aronson R; Windecker S; Mehran R; Lopes RD
    Circulation; 2020 May; 141(20):1618-1627. PubMed ID: 32223444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillation.
    Carnicelli AP; Al-Khatib SM; Xavier D; Dalgaard F; Merrill PD; Wojdyla DM; Lewis BS; Hanna M; Alexander JH; Lopes RD; Wallentin L; Granger CB
    Heart; 2021 May; 107(9):713-720. PubMed ID: 32938772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial.
    Zeitouni M; Giczewska A; Lopes RD; Wojdyla DM; Christersson C; Siegbahn A; De Caterina R; Steg PG; Granger CB; Wallentin L; Alexander JH;
    J Am Coll Cardiol; 2020 Mar; 75(10):1145-1155. PubMed ID: 32164888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Kidney Disease Stage G4: A Single-Center Experience.
    Heleniak Z; Papuga-Szela E; Krzysztof P; Anetta U
    J Cardiovasc Pharmacol; 2020 Dec; 76(6):671-677. PubMed ID: 33284572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial.
    Ezekowitz MD; Pollack CV; Halperin JL; England RD; VanPelt Nguyen S; Spahr J; Sudworth M; Cater NB; Breazna A; Oldgren J; Kirchhof P
    Eur Heart J; 2018 Aug; 39(32):2959-2971. PubMed ID: 29659797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial.
    Pol T; Held C; Westerbergh J; Lindbäck J; Alexander JH; Alings M; Erol C; Goto S; Halvorsen S; Huber K; Hanna M; Lopes RD; Ruzyllo W; Granger CB; Hijazi Z
    J Am Heart Assoc; 2018 Feb; 7(3):. PubMed ID: 29419390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial.
    Bahit MC; Vora AN; Li Z; Wojdyla DM; Thomas L; Goodman SG; Aronson R; Jordan JD; Kolls BJ; Dombrowski KE; Vinereanu D; Halvorsen S; Berwanger O; Windecker S; Mehran R; Granger CB; Alexander JH; Lopes RD
    JAMA Cardiol; 2022 Jul; 7(7):682-689. PubMed ID: 35612866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apixaban Versus Vitamin K Antagonists in Patients With Antiphospholipid Syndrome: A Cohort Study.
    Sikorska M; Chmiel J; Papuga-Szela E; Broniatowska E; Undas A
    J Cardiovasc Pharmacol; 2024 Jul; 84(1):36-44. PubMed ID: 38922590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex.
    Carnicelli AP; Hong H; Connolly SJ; Eikelboom J; Giugliano RP; Morrow DA; Patel MR; Wallentin L; Alexander JH; Cecilia Bahit M; Benz AP; Bohula EA; Chao TF; Dyal L; Ezekowitz M; A A Fox K; Gencer B; Halperin JL; Hijazi Z; Hohnloser SH; Hua K; Hylek E; Toda Kato E; Kuder J; Lopes RD; Mahaffey KW; Oldgren J; Piccini JP; Ruff CT; Steffel J; Wojdyla D; Granger CB;
    Circulation; 2022 Jan; 145(4):242-255. PubMed ID: 34985309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pattern and Impact of Off-label Underdosing of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Who are Indicated for Standard Dosing.
    Cho MS; Yun JE; Park JJ; Kim YJ; Lee J; Kim H; Park DW; Nam GB
    Am J Cardiol; 2020 May; 125(9):1332-1338. PubMed ID: 32098658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Difference in left atrial D-dimer level in patients with atrial fibrillation treated with direct oral anticoagulant.
    Watanabe T; Tachibana K; Shinoda Y; Minamisaka T; Fukuoka H; Inui H; Ueno K; Inoue S; Mine K; Hoshida S
    BMC Cardiovasc Disord; 2021 Oct; 21(1):487. PubMed ID: 34627142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study.
    Durand M; Schnitzer ME; Pang M; Carney G; Eltonsy S; Filion KB; Fisher A; Jun M; Kuo IF; Renoux C; Paterson JM; Quail J; Matteau A;
    CMAJ Open; 2020; 8(4):E877-E886. PubMed ID: 33355273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists.
    Lip GY; Rasmussen LH; Olsson SB; Jensen EC; Persson AL; Eriksson U; Wåhlander KF;
    Eur Heart J; 2009 Dec; 30(23):2897-907. PubMed ID: 19690349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticoagulants for Stroke Prevention in Atrial Fibrillation in Elderly Patients.
    Schäfer A; Flierl U; Berliner D; Bauersachs J
    Cardiovasc Drugs Ther; 2020 Aug; 34(4):555-568. PubMed ID: 32350792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial.
    Rao MP; Halvorsen S; Wojdyla D; Thomas L; Alexander JH; Hylek EM; Hanna M; Bahit MC; Lopes RD; De Caterina R; Erol C; Goto S; Lanas F; Lewis BS; Husted S; Gersh BJ; Wallentin L; Granger CB;
    J Am Heart Assoc; 2015 Dec; 4(12):. PubMed ID: 26627878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repeated Measurement of the Novel Atrial Biomarker BMP10 (Bone Morphogenetic Protein 10) Refines Risk Stratification in Anticoagulated Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial.
    Gkarmiris KI; Lindbäck J; Alexander JH; Granger CB; Kastner P; Lopes RD; Ziegler A; Oldgren J; Siegbahn A; Wallentin L; Hijazi Z
    J Am Heart Assoc; 2024 Apr; 13(7):e033720. PubMed ID: 38529655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials.
    Aulin J; Hijazi Z; Siegbahn A; Andersson U; Alexander JH; Connolly SJ; Ezekowitz MD; Gersh BJ; Granger CB; Horowitz J; Hylek EM; Lopes RD; Yusuf S; Wallentin L; Oldgren J
    J Thromb Haemost; 2020 Sep; 18(9):2287-2295. PubMed ID: 32510737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation.
    Kirchhof P; Haeusler KG; Blank B; De Bono J; Callans D; Elvan A; Fetsch T; Van Gelder IC; Gentlesk P; Grimaldi M; Hansen J; Hindricks G; Al-Khalidi HR; Massaro T; Mont L; Nielsen JC; Nölker G; Piccini JP; De Potter T; Scherr D; Schotten U; Themistoclakis S; Todd D; Vijgen J; Di Biase L
    Eur Heart J; 2018 Aug; 39(32):2942-2955. PubMed ID: 29579168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. D-dimer and risk of venous thromboembolism recurrence: Comparison of two studies with similar designs but different laboratory and clinical results.
    Palareti G; Legnani C; Tosetto A; Poli D; Testa S; Ageno W; Pengo V; Cosmi B; Prandoni P
    Thromb Res; 2024 Jun; 238():52-59. PubMed ID: 38669963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.